Molecularly Targeted Radionuclide Therapy Via the Integrin Alphavbeta6

This trial is testing a new type of targeted radiation therapy that uses a radioactive molecule designed to attach to a protein called integrin alphavbeta6, which is found on certain lung cancer cells. It includes a PET scan step to first confirm the target is present before proceeding to therapy. **You may be eligible if...** - You are 18 or older with confirmed metastatic non-small cell lung cancer (NSCLC) - Your cancer has progressed on at least one prior FDA-approved treatment - You have measurable disease on imaging - Tumor tissue from a prior biopsy is available - You are in adequate physical condition (ECOG ≤2) **You may NOT be eligible if...** - You have not received any prior treatment for your metastatic NSCLC - Your organ function is inadequate - You are pregnant or breastfeeding - You have uncontrolled infections or other serious medical conditions Talk to your doctor to see if this trial is right for you.